Epiodyne, Inc.
Opioid medicines precisely designed for minimal side effects and minimal addiction potential
San Francisco, United States · Founded 2018 · $2.8M raised
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2018
- Business Model
- B2B
- Website
- epiodyne.com
- Total Funding
- $2.8M
About
Epiodyne is a clinical-stage biopharmaceutical company developing small-molecule opioid medicines with precisely calibrated receptor pharmacology to address both pain management and opioid use disorder (OUD). Founded on research from UCSF, Stanford, and Duke, its lead program EPD-2520 selectively activates the mu opioid receptor to provide analgesia with reduced addiction potential and respiratory depression risk.
Summary
Epiodyne, Inc. is a Biotech company based in San Francisco, United States, founded in 2018. It has raised $2.8M in total.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Funding History
No funding data available yet.
Know something? Help us improve our data.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...